Low-density lipoprotein (LDL) comprises a heterogeneous
|
|
- Kory Boyd
- 5 years ago
- Views:
Transcription
1 Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype Winfried März, MD; Hubert Scharnagl, BSc; Claudia Abletshauser, MD; Michael M. Hoffmann, PhD; Aloys Berg, MD; Joseph Keul, MD; Heinrich Wieland, MD; Manfred W. Baumstark, PhD Background Although HMG-CoA reductase inhibitors (HMGRIs) are effective lipid-lowering agents, it remains controversial whether these agents also lower dense LDL (dldl), a predominance of which is considered to contribute to the atherogenicity of the metabolic syndrome. Methods and Results In a multicenter, double-blind, randomized, placebo-controlled study, we determined the effect of the HMGRI fluvastatin on lipids, apolipoproteins, and LDL subfractions (by equilibrium density gradient ultracentrifugation). A total of 52 postmenopausal women with combined hyperlipidemia and increased dldl were treated with either fluvastatin 40 mg/d (n 35) or placebo (n 17). After 12 weeks treatment, significant reductions (P 0.001) in total cholesterol ( 19%), IDL cholesterol ( 35%), LDL cholesterol ( 23%), apolipoprotein B ( 21%), and apolipoprotein B in dldl ( 42%) were apparent among fluvastatin recipients. No significant changes in triglycerides or HDL cholesterol were observed. The effect of fluvastatin on dldl was correlated with baseline values. There was no consistent relationship, however, between the effect of fluvastatin on triglycerides and the decrease in dldl. Conclusions Fluvastatin lowers total and LDL cholesterol and the concentration of dldl. This profile may contribute to an antiatherogenic effect for fluvastatin that is greater than expected on the basis of changes in lipids and apolipoproteins. (Circulation. 2001;103: ) Key Words: fluvastatin coronary disease lipoproteins Low-density lipoprotein (LDL) comprises a heterogeneous group of particles, of which the dense subfraction (dldl) is considered most atherogenic. 1 3 A link between dldl and increased risk of coronary heart disease (CHD) was first proposed by Austin and coworkers. 4 Subsequent case-control and prospective studies have shown that a predominance of dldl increases the risk of CHD by up to 7-fold Evidence for a role of dldl in CHD also comes from angiographic trials. In the St Thomas Atherosclerosis Regression Study, patients showing regression of coronary atherosclerosis had low concentrations of dldl during treatment. 13 Dense LDLs are associated with other components of the metabolic syndrome, particularly elevated triglycerides and low HDL cholesterol (HDL-C). The independent contribution of dldl to the risk of CHD has therefore been difficult to determine. Thus, LDL subclass profile remained predictive of CHD after adjustment for triglycerides or HDL in some 9,11 but not all studies. 6 8,10,12 Very recently, 14 dldls were shown to cause endothelial dysfunction independent of LDL cholesterol (LDL-C), triglycerides, and HDL-C. Clearly, any therapeutic principle that lowers LDL-C and triglycerides and raises HDL-C might therefore be enhanced by a reduction in dldl. The effects of HMG-CoA reductase inhibitors (HM- GRIs) on LDL subfractions have been studied by gradient gel electrophoresis (GGE) and ultracentrifugation Providing a coarse estimate of the size distribution of LDL rather than the concentration of dldl, GGE did not reveal increases of the average LDL diameter during HMGRI treatment. 16,19,20,25 Some of the ultracentrifugation-based studies showed a decrease of the concentration of dldl 15,19 on HMGRI; others did not. 18,19,22 24 It is thus controversial whether these agents lower dldl. The HM- GRI fluvastatin offers a wide spectrum of clinical benefits in various patient subgroups, including the elderly. 26 We therefore examined the effect of short-term therapy with fluvastatin on dldl levels in patients at increased risk of CHD, namely, postmenopausal women with an atherogenic lipoprotein profile. Received September 6, 2000; revision received January 16, 2001; accepted January 22, From the Division of Clinical Chemistry (W.M., H.S., M.M.H., H.W.) and the Division of Sports Medicine, Department of Medicine (A.B., J.K., M.W.B.), Albert Ludwigs-University, Freiburg, Germany; and Novartis Pharma AG, Nürnberg, Germany (C.A.). Dr Abletshauser is an employee of Novartis Pharma AG, Nürnberg, Germany, and Dr März serves as one of its consultants. Novartis Pharma AG provided financial support for this study. Correspondence to Winfried März, MD, Department of Medicine, Hugstetter Straße 55, D Freiburg, Germany. maerz@med1.ukl.uni-freiburg.de 2001 American Heart Association, Inc. Circulation is available at
2 März et al Fluvastatin and Dense LDL 1943 Methods Study Design This was a double-blind, randomized, placebo-controlled, 20-week study comprising an 8-week run-in phase followed by an active treatment period of 12 weeks, conducted at 10 sites in Germany. The study protocol was approved by the Ethics Committee of the University of Freiburg and the institutional review boards at each study site. All patients gave informed, written consent. Patients A total of 52 postmenopausal women ( 12 months since last menstrual period, levels of follicle-stimulating hormone 28 IU/L), 44 to 75 years old, with LDL-C 150 mg/dl, triglycerides 120 mg/dl, and apolipoprotein (apo) B in dldl (LDL-5 LDL-6) 25 mg/dl, participated. Major exclusion criteria were LDL-C 300 mg/dl; triglycerides 500 mg/dl; acute myocardial infarction within 3 months of study commencement; insulin-dependent diabetes mellitus or poorly controlled non insulin-dependent diabetes mellitus (glucose 150 mg/dl or HbA 1c 8%); severe obesity; overt liver disease; chronic renal failure; myopathy; alcohol or drug abuse; several other significant diseases; known hypersensitivity to HMGRIs; or use of other lipid-lowering therapy, immunosuppressants, erythromycin and/or neomycin, ketoconazole, and hormone-replacement therapy. Patients commenced an 8-week run-in period, during which previous lipid-lowering therapy was discontinued. Dietary advice was provided according to the American Heart Association Step I diet, and patients were requested to maintain smoking habits, physical activity, and alcohol consumption. After the run-in phase, patients were randomized to receive either fluvastatin 40 mg every evening (n 35) or placebo (n 17) for 12 weeks. A randomization ratio of 2:1 was selected to reduce the number of patients receiving the potentially inferior treatment. At week 6, concomitant diseases, adverse events, and compliance (capsule counting) were recorded, and at week 12, laboratory assessments and physical examinations were repeated. Laboratory Assessments Two weeks before randomization (baseline) and after 12 weeks active treatment, fasting venous blood samples were drawn. Serum samples were stored up to 1 week at 4 C before lipoprotein subfractionation. Previous experiments indicated that the lipid and lipoprotein measurements were not affected by storage at 4 C for 1 week. All laboratory assessments were performed centrally at the Department of Medicine, University of Freiburg, Germany. Lipids and Apolipoproteins Cholesterol, triglycerides, and phospholipids were measured with enzymatic methods, calibrated with secondary standards from Roche Diagnostics. ApoB was determined by kinetic nephelometry (Behring), standardized by reference to the Centers for Disease Control standard. 27 Lipid and apob measurements had coefficients of variation of 5%. Lipoproteins and Lipoprotein Subfractions Quantitative lipoprotein electrophoresis 28 was used to estimate LDL-C before subfractionation at week 2. VLDL (d kg/l), IDL ( d kg/l), LDL (1.019 d kg/l), and HDL (1.065 d 1.21 kg/l) were isolated by ultracentrifugation. 29 LDL was subsequently fractionated into 6 density classes by equilibrium density gradient centrifugation. 27 LDL subfractions were quantified by measurement of lipids and apob. The coefficients of variation for the analysis of cholesterol, free cholesterol, phospholipids, and apob in LDL subfractions were 7% (and 10% in the case of triglycerides). Radii of LDL subfractions were calculated as described. 27 Statistical Methods Contingency tables were analyzed by Fisher s exact test. Intraindividual changes between baseline and week 12 were calculated and TABLE 1. Summary of Baseline Demographic and Clinical Characteristics Parameter Fluvastatin (n 35) Placebo (n 17) Age, y (mean SD) Body mass index, baseline, kg/m (mean SD) Body mass index, week 12, kg/m (mean SD) Coronary heart disease, n (%) 10 (29) 4 (24) Peripheral vascular disease, n (%) 1 (3) 0 Cerebrovascular disease, n (%) 0 1 (6) Diabetes mellitus, n (%) 3 (9) 3 (18) Hypertension, n (%) 3 (9) 2 (12) Current smoker, n (%) 2 (6) 2 (12) Lipids and lipoproteins, mg/dl (mean SD) Total cholesterol LDL-C HDL-C Total triglycerides Total apob ApoB in dldl* *LDL-5 LDL-6 fraction. compared between treatment groups by Student s t test. Bivariate correlations were analyzed by Pearson s correlation coefficients. A value of P 0.05 was considered significant. Results A total of 162 women were included in the dietary run-in period, of whom 52 (32%) met the inclusion criterion regarding apob in dldl ( 25 mg/dl) and were randomized. All randomized patients completed the study according to protocol. Overall, the 2 treatment groups were comparable in terms of clinical characteristics and baseline lipid and lipoprotein concentrations (Table 1). There was no significant difference in the changes of body mass index between groups (P 0.382). Patients were recruited from 10 centers, 1 of which was overrepresented (providing 11 and 6 patients in the fluvastatin and placebo groups, respectively). Exclusion of patients at this center from the statistical analyses did not affect the study findings. Changes in Lipids, Lipoproteins, and Apolipoproteins After 12 weeks treatment, significant reductions in total cholesterol, LDL-C, and total apob were observed among fluvastatin recipients compared with placebo (Table 2). Triglycerides and HDL-C did not change significantly. Major ApoB-Containing Lipoproteins No significant changes in VLDL constituents were observed (Table 3). More marked changes were apparent for IDL. With the exception of triglycerides (decrease by 9%), all constituents of IDL decreased by 35%, with apob in IDL decreasing by almost 30% (Table 3). With regard to LDL, total
3 1944 Circulation April 17, 2001 TABLE 2. Effect of Fluvastatin (40 mg/d) on Mean ( SD) Lipids and ApoB Levels Fluvastatin (n 35) Placebo (n 17) Parameter Baseline Study End % Change Baseline Study End % Change P Total cholesterol LDL-C HDL-C NS Total triglycerides NS Total apob Values are mg/dl. cholesterol decreased by 23%, and apob in LDL decreased by 24%; similar changes were observed for esterified and nonesterified cholesterol and phospholipid content (Table 3). Relative to placebo, the effect of fluvastatin on LDL triglycerides ( 14%) was not statistically significant. No significant changes in particle radius were apparent for VLDL, IDL, or LDL during fluvastatin therapy (Table 3). LDL Subfractions Among LDL subfractions, the most marked changes were observed in LDL-5 and LDL-6 (Figure 1). Fluvastatin lowered lipids and apob in LDL-5 by 40% to 45% (Table 4). In LDL-6, the respective reductions ranged from 36% to 42%, with the exception of triglycerides, which decreased by 25% (Table 4). For dldl (LDL-5 LDL-6), relative changes were 39% to 44% for apob, cholesterol, and phospholipids and 33% for triglycerides (Table 4). Less marked (but statistically significant) changes in the concentration of LDL-4 were also observed, whereas the lightest subfractions (LDL-1 and LDL-2) remained unaffected (Figure 1). Correlation Analysis The decrease in LDL-6 apob was most closely related to the levels of LDL-6 apob before treatment (r 0.878, P 0.001), ie, the higher the baseline LDL-6 apob level, the greater the reduction evoked by fluvastatin (Figure 2). Total TABLE 3. Effect of Fluvastatin (40 mg/d) on Mean ( SD) Composition and Particle Radius of ApoB-Containing Lipoproteins Fluvastatin (n 35) Placebo (n 17) Lipoprotein/Constituent Baseline Study End Baseline Study End P VLDL Cholesterol NS Nonesterified cholesterol NS Esterified cholesterol NS Triglycerides NS Phospholipids NS ApoB NS Particle radius NS IDL Cholesterol Nonesterified cholesterol Esterified cholesterol Triglycerides NS Phospholipids ApoB Particle radius NS LDL Cholesterol Nonesterified cholesterol Esterified cholesterol Triglycerides NS Phospholipids ApoB Particle radius NS Values are mg/dl except for particle radius (nm).
4 März et al Fluvastatin and Dense LDL 1945 TABLE 4. Effect of Fluvastatin (40 mg/d) on Mean ( SD) Composition and Particle Radius of the dldl Fraction Fluvastatin (n 35) Placebo (n 17) Fraction/Constituent Baseline Study End Baseline Study End P LDL-1 Cholesterol NS Nonesterified cholesterol Esterified cholesterol NS Triglycerides NS Phospholipids NS ApoB Particle radius NS LDL-5 Cholesterol Nonesterified cholesterol Esterified cholesterol Triglycerides Phospholipids ApoB Particle radius NS LDL-6 Cholesterol Nonesterified cholesterol Esterified cholesterol Triglycerides Phospholipids ApoB Particle radius NS LDL-5 LDL-6 Cholesterol Nonesterified cholesterol Esterified cholesterol Triglycerides Phospholipids ApoB Values are mg/dl except for particle radius (nm). triglycerides (r 0.403, P 0.016) and VLDL apob (r 0.589, P 0.001) were weaker, albeit significant, predictors of the change in LDL-6 apob. Interestingly, positive correlations were obtained between apob in LDL-2 to LDL-4 and the change in LDL-6 apob, ie, the higher the apob level in these fractions, the smaller the change in LDL-6 apob during fluvastatin therapy (Figure 2). Changes in Triglycerides and LDL Subfractions An inverse correlation between triglycerides and dldl was described previously. 5,6,30 We therefore examined whether the decrease in dldl was associated with changes in triglycerides. The overall correlation between change in triglycerides and change in LDL-6 apob was weak (r 0.101). Only in those patients showing triglyceride reductions during fluvastatin therapy (n 23; mean reduction 27%) did changes in LDL-6 apob correlate significantly with changes in triglycerides (r 0.655, P 0.001). The remaining patients (n 12) showed a mean increase in triglycerides of 50%, but experienced a substantial decrease in LDL-6 apob as well (average of 19.6 mg/dl, compared with 5.7 mg/dl in those patients showing a decrease in triglycerides). Safety and Tolerability Fluvastatin was well tolerated, and there were no safety concerns. Mean serum levels of total bilirubin, transaminases, alkaline phosphatase, -glutamyl transferase, and creatine phosphokinase did not change. Discussion Of available lipid-lowering agents, it is generally believed that only fibrates 1,21,23,31 33 and niacin 34 have the potential to alter the distribution of LDL subclasses. Indeed, most reports using GGE or ultracentrifugation to study the effects of
5 1946 Circulation April 17, 2001 Figure 1. Concentration of apob in lipoprotein fractions and subfractions in 52 postmenopausal women receiving fluvastatin (n 35; left) or placebo (n 17; right). Squares indicate week 2; circles, week 12. *P 0.01 and **P HMGRIs on the distribution of LDL subfractions have been negative. 16,18 20,22,25 Two ultracentrifugation-based reports indicated that HMGRIs lowered dldl. 18,22 For fluvastatin, 2 negative studies have been published. 24,25 Given the inconsistency of these investigations, we examined the effect of fluvastatin on dldl in patients at increased risk of CHD with an atherogenic lipoprotein profile. Because we were aware that an atherogenic lipoprotein profile appears to have a greater impact on cardiovascular risk in women than in men, 35 the study was performed in postmenopausal women. Our major finding was that fluvastatin decreased dldl by 40%, an effect that was almost twice the change in total LDL-C ( 23%). Buoyant LDL subfractions did not change, whereas IDL (which includes atherogenic remnants of triglyceride-rich lipoproteins) decreased by 30%. In designing the study, we expected that substantial reductions in dldl would be seen in individuals exhibiting high concentrations of dldl at baseline. Hence, we selectively recruited women with apob in dldl 25 mg/dl, which approximately corresponds to the median in postmenopausal women (unpublished observations). This assumption was confirmed in the present study. Our findings contrast with the general literature pertaining to the effect of HMGRI on LDL subfractions. There are subtle differences, however, between the present and previous studies. For example, most studies derived LDL subfraction distribution from measurements of LDL peak particle size by GGE. 16,17,19,20,24,25 Similarly, we were unable to detect a significant increase in the mean size of whole LDL when particle radius was calculated according to a previously published algorithm. 27 This is surprising, given the substantial reduction in dldl, but consistent with theoretical considerations. Using the concentrations and particle radii of all LDL subfractions, we calculated the expected radii for whole LDL at baseline and at week 12 as weighted means of the individual LDL subfractions. This yielded particle radii of 9.8 and 9.9 nm, respectively, at these time points, values close to those determined empirically (9.7 and 9.9 nm, respectively; Table 3). Provided that there are no substantial changes in the sizes of individual subfractions, it cannot therefore be ex- Figure 2. Correlation between change in LDL-6 apob level after treatment with fluvastatin (40 mg/d) and either baseline apob level in various lipoprotein fractions (a through h) or change in total triglycerides (i) among 35 patients with combined hyperlipidemia. i, Squares indicate patients in whom triglycerides decreased, and circles indicate patients in whom triglycerides increased. The regression line applies to patients with triglyceride decreases only.
6 März et al Fluvastatin and Dense LDL 1947 pected that the changes of LDL-5 and LDL-6 in the present study would translate into more than a small change of the average size of the whole LDL fraction. Other studies that used ultracentrifugation for LDL subfractionation did not specifically select patients on the basis of an atherogenic lipoprotein profile. 18,22 In this context, it is noteworthy that 3 GGE-based studies that included such patients were small ( 12 patients) and may therefore have been underpowered. 16,19,25 The difference in findings between the present investigation and other ultracentrifugation-based studies 15,18,21 23,36 may have methodical reasons. If ultracentrifugation is not performed until complete equilibrium is reached (as in the present study), separation may be driven not only by density but also by particle size. Other explanations may relate to the study design. For example, most studies that used ultracentrifugation failed to specifically select for individuals with elevated dldl at baseline, 15,18,21 23,36 and some lacked placebo groups. 15,18,22,23,36 The mechanisms by which fluvastatin selectively decreased the most atherogenic lipoprotein fractions, IDL and dldl, remain elusive. One potential mechanism relates to the effect of HMGRIs on the release of triglyceride-rich particles in the liver, because an inverse correlation exists between dldl and triglycerides. 5,6,30 Surprisingly, however, there was no consistent relationship between changes in triglycerides and dldl for the overall patient population, ruling out the possibility that alterations in VLDL metabolism (eg, reduced secretion of VLDL or high lipoprotein lipase activity) fully accounted for the changes in dldl. The latter finding contrasts with those of Tilly-Kiesi, 15 who reported decreases in dldl on lovastatin only in those individuals who responded with decreases in triglycerides. Treatment with fluvastatin stimulates the expression of hepatic LDL receptors, 37 which also catabolize IDL. 38 The most obvious explanation for the decrease in IDL in the present study is therefore that these lipoproteins are taken up by LDL receptors at an enhanced rate during fluvastatin therapy. The change in dldl is less easily explained, because these particles are poor ligands of LDL receptors, 2 and other, less evident, mechanisms might be active. One possible mechanism, an altered rate of transfer of cholesteryl esters from HDL to apob-containing lipoproteins, 39 was ruled out by the finding that activity of cholesteryl ester transfer protein was unchanged during fluvastatin therapy (not shown). Another potential mechanism focuses on hepatic lipase, which has been implicated in the generation of dldl In individuals showing high concentrations of triglyceride-rich lipoproteins, transfer of triglycerides (in exchange with cholesteryl esters) into LDL and HDL may occur; these triglycerides may then be hydrolyzed by hepatic lipase, leading to the formation of smaller, lipid-depleted particles. 39 In the present study, significant correlations were found between the decreases in LDL-5 and LDL-6 and an increase of HDL-2b, the most buoyant HDL subfraction (not shown). Because buoyant HDL particles are the preferred substrate of hepatic lipase, this would accord with the suggestion of decreased hepatic lipase during fluvastatin therapy. This is also supported by Hoogerbrugge and Jansen, 43 who found that atorvastatin lowers hepatic lipase. The possibility that our results were confounded by lifestyle changes and/or concomitant cardiovascular therapy (eg, antihypertensive drugs) warrants discussion. For example, other authors have shown that -adrenergic receptor antagonists raise both IDL 44 and dldl. 8 In total, 7 patients (fluvastatin, n 5; placebo, n 2) received -adrenergic receptor antagonists, and no patient received -adrenergic receptor blocking agents. Thus, the proportion of patients receiving -adrenergic receptor antagonists was small and comparable for each treatment group, and no dosage adjustments were made during the study. Exclusion of these patients from the statistical analyses had no effect on the statistical significance of the findings, indicating that concomitant -blocker therapy did not affect our results to a relevant extent. Exclusion of diabetic individuals also did not affect the statistical significance of our results (P for the change in dldl for all patients, P for the nondiabetic patients). A similar conclusion can be drawn with regard to the potential confounding effect of lifestyle changes. Thus, although patients were not requested to formally record their dietary habits and degree of exercise during the study (rather, patients were advised to adhere to a lipid-modified diet and not change usual exercise habits), there is no reason to assume that minor changes occurred more frequently in the fluvastatin group than in those treated with placebo. Moreover, there was no significant difference between the changes in body mass index for either treatment group. ANOVA using the change of dldl as the dependent variable, treatment as the independent variable, and the variation of body mass index as a covariable says that changes in LDL subfractions remain significant after adjustment for body mass index (data not shown). In conclusion, fluvastatin produces a shift in LDL subfractions toward more buoyant, less atherogenic LDL particles in patients at increased risk of CHD. This profile may contribute to an antiatherogenic effect for fluvastatin that is greater than expected on the basis of changes in lipids and apolipoproteins. Acknowledgments The authors thank Novartis Pharma AG, Nürnberg, Germany, for financial support and Sabiene Jotterand, Dagmar Reduth, Gisela Zöllner, and Rita Glaeser for technical assistance. References 1. de Graaf J, Hendriks JC, Demacker PN, et al. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arterioscler Thromb. 1993;13: Nigon F, Lesnik P, Rouis M, et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32: Galeano NF, Al-Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL-receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res. 1998;39: Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260: Austin MA, King M-C, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease. Circulation. 1990;82:
7 1948 Circulation April 17, Campos H, Genest JJ, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12: Coresh J, Kwiterovich PO Jr, Smith HH, et al. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34: Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106: Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276: Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276: Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95: Gray RS, Robbins DC, Wang W, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 1997;17: Watts GF, Mandalia S, Brunt JN, et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas Atherosclerosis Regression Study (STARS). Metabolism. 1993;42: Vakkilainen J, Mäkimattila S, Seppälä-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation. 2000;102: Tilly-Kiesi M. The effect of lovastatin on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism. 1991;40: Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 1993;102: Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb. 1993;13: de Graaf J, Demacker PN, Stalenhoef AF. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med. 1993;43: Franceschini G, Cassinotti M, Vecchio G, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb. 1994;14: Zambon S, Cortella A, Sartore G, et al. Pravastatin treatment in combined hyperlipidaemia: effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol. 1994;46: Bredie SJ, de Bruin TW, Demacker PN, et al. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-b-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 1995;75: Guerin M, Dolphin PJ, Talussot C, et al. Pravastatin modulates cholesteryl ester transfer from HDL to apob-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15: Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996;7: Yuan J, Tsai MY, Hegland J, et al. Effects of fluvastatin (XU ), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991;87: Superko HR, Krauss RM, Di Ricco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol. 1997;80: Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs. 1999;57: Baumstark MW, Kreutz W, Berg A, et al. Structure of human low-density lipoprotein subfractions, determined by x-ray small-angle scattering. Biochim Biophys Acta. 1990;1037: Wieland H, Seidel D. Improved assessment of plasma lipoprotein patterns, IV: simple preparation of a lyophilized control serum containing intact human plasma lipoproteins. Clin Chem. 1982;28: Lindgren FT. Preparative ultracentrifuge laboratory procedures and suggestions for lipoprotein analysis. In: Perkins EG, ed. Analysis of Lipids and Lipoproteins. Champaign, Ill: American Oil Chemical Society; 1975: McNamara JR, Jenner JL, Ji Z, et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12: Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis. 1992;95: Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 1993;100: Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16: Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992;95: Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol. 1992;2: Gaw A, Packard CJ, Murray EF, et al. Effects of simvastatin on apob metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993;13: Hayashi K, Kurokawa J, Nomura S, et al. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-a reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim Biophys Acta. 1993;1167: Soutar AK, Myant NB, Thompson GR. The metabolism of very-lowdensity and intermediate-density lipoproteins in patients with familial hypercholesterolemia. Atherosclerosis. 1982;43: Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17: Zambon A, Austin MA, Brown BG, et al. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 1993;13: Watson TDG, Caslake MJ, Freeman DJ, et al. Determinants of lowdensity lipoprotein subfraction distribution and concentrations in young normolipidemic subjects. Atherosclerosis. 1994;107: Tan CE, Forster L, Caslake MJ, et al. Relations between plasma lipids and postheparin plasma lipases and VLDL subfractions in normolipidemic men and women. Arterioscler Thromb Vasc Biol. 1995;15: Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis. 1999;146: Superko HR, Wood PD, Krauss RM. Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclass, and postprandial lipemia. Am J Med. 1989; 86(suppl 1B):26 31.
Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationN-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP
Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA
More informationRosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationInfluence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia
Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia B. M. Schamberger, H. C. Geiss, M. M. Ritter, P. Schwandt, and K. G. Parhofer 1 Department
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationRole of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels. Small Dense KATAGIRI, MD, FJCC
J Cardiol 2000 ; 36: 371 378 Small Dense Role of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels Shinji Tsutomu Taro Keiko Takeshi Minoru Hiroshi
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationThe Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes
128 Original Article The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes Anna Tokuno 1, Tsutomu Hirano 1, Toshiyuki Hayashi 1, Yusaku
More informationMeasurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date
MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationBIOCHEMISTRY BLOOD - SERUM Result Range Units
BIOCHEMISTRY BLOOD - SERUM Result Range Units LIPIDS CHOLESTEROL 3.9 0.0-5.5 mmol/l TRIGLYCERIDES 0.7 < 1.5 mmol/l LIPID STUDIES HDL(Protective) 1.5 > 1.2 mmol/l LDL(Atherogenic) 2.1 0.5-3.5 mmol/l Cholesterol/HDL
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationStudy of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases
Original article: Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Dr Abhijit Nikam, Dr Sonu Yadav, Dr Vivek Chiddarwar, Dr A L Kakrani Dept of Medicine,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLDL particle size: an important drug target?
LDL particle size: an important drug target? I. Rajman, Patrick I. Eacho 1, P. J. Chowienczyk 2 & J. M. Ritter 2 Clinical Pharmacology, Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Windlesham,
More informationRelationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease
Atherosclerosis 128 (1997) 235 240 Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease Martin Halle*, Daniel König,
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationSMALL-SIZE LOW-DENSITY LIPOPROtein
ORIGINAL CONTRIBUTION Low-Density Lipoprotein Size, Pravastatin Treatment, and Coronary Events Hannia Campos, PhD Lemuel A. Moye, MD Stephen P. Glasser, MD Meir J. Stampfer, MD, DPH Frank M. Sacks, MD
More informationFamilial combined hyperlipidemia (FCH) was first described
Clinical Investigation and Reports Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study Mario J. Veerkamp, MD; Jacqueline de Graaf, MD, PhD; Jan C.M.
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationUnit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationH. Robert Superko, MD a,b, *, Kaspar K. Berneis, MD c, Paul T. Williams, PhD d, Manfredi Rizzo, MD d,e, and Peter D.
Gemfibrozil Reduces Small Low-Density Lipoprotein More in Normolipemic Subjects Classified as Low-Density Lipoprotein Pattern B Compared With Pattern A H. Robert Superko, MD a,b, *, Kaspar K. Berneis,
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationcomposition with premature coronary artery disease in men and women
Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women Josef Coresh,' Peter 0. Kwiterovich,
More informationWalter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI
Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationClinical Investigation and Reports
Clinical Investigation and Reports Effect of 7-Year Infancy-Onset Dietary on Serum Lipoproteins and Lipoprotein Subclasses in Healthy Children in the Prospective, Randomized Special Turku coronary Risk
More informationRecently reported clinical trials have provided strong
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions The Atherosclerosis Risk in Communities (ARIC)
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationLipid profile in Diabetes Mellitus
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 2 (2017) pp. 123-131 Research India Publications http://www.ripublication.com Lipid profile in Diabetes Mellitus
More informationCARDIO Test INFAI. for Cardiac Risk Assessment
CARDIO Test INFAI for Cardiac Risk Assessment Heart Attack and Stroke: A Worldwide Problem NMR analysis of serum to assess the risk of cardiovascular disease Headquarter in Cologne (RTZ) Facility in Bochum
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationLipid modification in type 2 diabetes: the role of LDL and HDL
REVIEW ARTICLE doi: 10.1111/j.1472-8206.2009.00739.x Lipid modification in type 2 diabetes: the role of LDL and HDL Bruno Vergès* Service d Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital
More informationLipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More information5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT
5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT Prof. Victor Blaton, Ph.D. Department of Clinical Chemistry, Hospital AZ Sint-Jan
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationIntroduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)
Introduction Hyperlipidemia, or hyperlipoproteinemia, is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemias are divided in primary and secondary
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationChapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
More informationPlasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam
Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain
More informationPreferential Cholesteryl Ester Acceptors Among the LDL Subspecies of Subjects With Familial Hypercholesterolemia
679 Preferential Cholesteryl Ester Acceptors Among the LDL Subspecies of Subjects With Familial Hypercholesterolemia Maryse Guerin, Peter J. Dolphin, M. John Chapman Abstract Elevated cholesteryl ester
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationLipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?
Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history
More informationEpidemiological studies have shown an association between
Change in 1 HDL Concentration Predicts Progression in Coronary Artery Stenosis Bela F. Asztalos, Marcelo Batista, Katalin V. Horvath, Caitlin E. Cox, Gerard E. Dallal, Josh S. Morse, Greg B. Brown, Ernst
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23794
More informationDyslipidemia. (Med-341)
Dyslipidemia (Med-341) Anwar A Jammah, MD, FRCPC, FACP, CCD, ECNU. Associate Professor of Medicine Consultant Medicine, Endocrinology, Thyroid Oncology Department of Medicine, King Saud University The
More informationLipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More information